Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5249338 | 0.99 | HTR2A (0.73) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL18294757 | 0.92 | HTR2A (0.63) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL20274301 | 0.92 | HTR2A (0.63) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL5253687 | 0.90 | HTR2A (0.72) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL5249544 | 0.89 | HTR2A (0.71) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL5256062 | 0.87 | HTR2A (0.67) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL5251014 | 0.86 | HTR2A (0.66) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Roluperidone SCHEMBL5252391 | 0.85 | HTR2A (1.00) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Roluperidone SCHEMBL5248131 | 0.84 | HTR2A (0.98) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Roluperidone SCHEMBL5253902 | 0.84 | HTR2A (0.96) | HTR2AHTR1ATMEM97HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | claimed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | claimed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | claimed |
| EP-3135286-B1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA AND SYMPTOMS THEREOF | MINERVA NEUROSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-4070794-A2 | METHODS OF USE CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR-MEDIATED DISORDERS | Minerva Neurosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210106573-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | MINERVA NEUROSCIENCES, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3157926-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10179776-B2 | Compounds and methods of use to treat schizophrenia | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180155318-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155318-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9884872-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20130274290-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | CYRENAIC PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274289-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274290-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | CYRENAIC PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012012542-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155318-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CHAT, GRIN2A, GRIN2C | HTR2A 159/4885HTR1A 423/4885TMEM97 1376/4885 |
| US-10179776-B2 | Compounds and methods of use to treat schizophrenia | SIGMAR1, GRIN2C, OPRL1 | HTR2A 78/4885HTR1A 66/4885TMEM97 39/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR2A 153/4885HTR1A 79/4885TMEM97 10/4885 |
| US-20210106573-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | SIGMAR1, CNR2, HCRTR2 | HTR2A 4/4885HTR1A 28/4885TMEM97 31/4885 |
| US-20130274290-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | SIGMAR1, CNR2, HCRTR2 | HTR2A 4/4885HTR1A 28/4885TMEM97 31/4885 |
| US-20130274289-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CHAT, GRIN2A, GRIN2C | HTR2A 159/4885HTR1A 423/4885TMEM97 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.